632.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IDXX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$639.60
Aprire:
$635.59
Volume 24 ore:
633.61K
Relative Volume:
1.13
Capitalizzazione di mercato:
$50.51B
Reddito:
$4.30B
Utile/perdita netta:
$1.06B
Rapporto P/E:
48.38
EPS:
13.076
Flusso di cassa netto:
$1.04B
1 W Prestazione:
-8.95%
1M Prestazione:
-5.59%
6M Prestazione:
+18.12%
1 anno Prestazione:
+34.86%
Idexx Laboratories Inc Stock (IDXX) Company Profile
Nome
Idexx Laboratories Inc
Settore
Industria
Telefono
(207) 556-0300
Indirizzo
ONE IDEXX DRIVE, WESTBROOK, ME
Confronta IDXX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
632.56 | 51.07B | 4.30B | 1.06B | 1.04B | 13.08 |
|
TMO
Thermo Fisher Scientific Inc
|
570.09 | 218.58B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.60 | 157.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
A
Agilent Technologies Inc
|
132.14 | 38.38B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 39.38B | 15.90B | 1.28B | 2.21B | 7.2842 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-31 | Aggiornamento | Stifel | Hold → Buy |
| 2025-10-01 | Iniziato | UBS | Neutral |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-01 | Iniziato | Jefferies | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | BTIG Research | Buy |
| 2024-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-12-04 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Downgrade | Stifel | Buy → Hold |
| 2022-07-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-07-12 | Iniziato | Piper Sandler | Overweight |
| 2022-05-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-08 | Iniziato | Atlantic Equities | Overweight |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-17 | Iniziato | Barclays | Overweight |
| 2019-09-09 | Iniziato | Goldman | Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Buy |
| 2018-11-02 | Reiterato | BofA/Merrill | Buy |
| 2018-05-07 | Reiterato | Stifel | Buy |
| 2018-01-16 | Iniziato | Piper Jaffray | Overweight |
| 2017-08-23 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Aggiornamento | CL King | Neutral → Buy |
| 2017-02-03 | Downgrade | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Ripresa | BofA/Merrill | Neutral |
| 2016-08-16 | Reiterato | Stifel | Buy |
| 2016-08-03 | Aggiornamento | Northcoast | Sell → Neutral |
| 2016-07-20 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-19 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-01 | Iniziato | CL King | Neutral |
| 2016-03-21 | Reiterato | Stifel | Buy |
| 2016-02-04 | Iniziato | Credit Suisse | Outperform |
| 2015-10-29 | Reiterato | Stifel | Buy |
| 2015-08-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Reiterato | Stifel | Buy |
| 2015-07-23 | Reiterato | Canaccord Genuity | Buy |
Mostra tutto
Idexx Laboratories Inc Borsa (IDXX) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Lonza Group (OtherLZAGY) - The Globe and Mail
IDEXX Laboratories Analysts Cut Their Forecasts Following Q4 Results - Benzinga
Roku To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 - marketscreener.com
UBS Adjusts IDEXX Laboratories PT to $730 From $750 - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 earnings call transcript - MSN
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 Earnings Call Transcript - Insider Monkey
BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 - marketscreener.com
IDEXX Laboratories, Inc. $IDXX Shares Sold by Villere ST Denis J & Co. LLC - MarketBeat
Thrivent Financial for Lutherans Has $38.68 Million Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories: Can This Quiet Diagnostics Powerhouse Still Surprise Wall Street? - AD HOC NEWS
BTIG Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $800 - 富途牛牛
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 14.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips - Investing.com Canada
IDEXX Laboratories (NASDAQ:IDXX) Trading Down 6.9%Should You Sell? - MarketBeat
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories Inc (IDXX) Q4 2025 Earnings Call Highlights: - GuruFocus
IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise - The Globe and Mail
Why Is IDEXX Labs Stock Falling Today? - Benzinga
IDEXX Laboratories Q4 Earnings Call Highlights - MarketBeat
IDEXX Laboratories (IDXX) Reports Strong Q4 2025 Performance - GuruFocus
RSI Alert: Idexx Laboratories (IDXX) Now Oversold - Nasdaq
IDEXX Laboratories Reports 14% Q4 Revenue Growth Driven by Premium Instrument Placements - Market Business Insights
IDEXX falls 4% following in-line 2026 guidance - Seeking Alpha
IDEXX beats the Street on Q4 results, issues initial 2026 guidance - Mainebiz
AI for investors - MLQ.ai
IDEXX Laboratories (NASDAQ:IDXX) Updates FY 2026 Earnings Guidance - MarketBeat
Earnings Summary: IDEXX Laboratories Q4 - Benzinga
IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics - marketscreener.com
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
IDEXX Laboratories (IDXX) Q4 FY25 sales rise in double digits - AlphaStreet
IDEXX Laboratories (NASDAQ:IDXX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
IDEXX LABORATORIES INC (NASDAQ:IDXX) Reports Strong Q4 2025 Earnings Beat, Issues Cautious 2026 Outlook - Chartmill
IDEXX Laboratories Q4 Comparable Earnings, Revenue Rise; Issues 2026 Guidance - marketscreener.com
Idexx: Q4 Earnings Snapshot - Bitget
IDEXX LABS ($IDXX) Releases Q4 2025 Earnings - Quiver Quantitative
IDEXX Laboratories Guides FY26 In Line With EstimatesUpdate - Nasdaq
IDEXX Laboratories Q4 Earnings Assessment - Benzinga
IDEXX Labs beats revenue expectations, shares dip slightly on guidance By Investing.com - Investing.com Australia
IDEXX Labs earnings missed by $0.01, revenue topped estimates By Investing.com - Investing.com Nigeria
(IDXX) IDEXX Laboratories Expects 2026 Revenue Range $4.63B$4.72B, vs. FactSet Est of $4.66B - marketscreener.com
(IDXX) IDEXX Laboratories Expects 2026 EPS Range $14.29$14.80, vs. FactSet Est of $14.45 - marketscreener.com
Earnings Flash (IDXX) IDEXX Laboratories Posts Q4 Comparable EPS $2.92, vs. FactSet Est of $2.93 - marketscreener.com
IDEXX Labs earnings missed by $0.01, revenue topped estimates - Investing.com South Africa
IDEXX Labs beats revenue expectations, shares dip slightly on guidance - Investing.com
IDEXX Laboratories Q4 Earnings Summary & Key Takeaways - Benzinga
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results - marketscreener.com
National Pension Service Has $74.81 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Principal Financial Group Inc. Purchases 187,967 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Idexx Laboratories Inc Azioni (IDXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):